Home » Healthcare » Pharmaceuticals » Polymyositis Treatment Market

Polymyositis Treatment Market By Type Of Drug Class (Immunosuppressant, Alkylating Agent, Immunoglobulin, Monoclonal Antibodies, Corticosteroids) – Growth, Future Prospects And Competitive Landscape, 2019 – 2027

Summary
Table Of Content

Market Synopsis

The polymyositis treatment market is projected to grow at a CAGR of 5.9% during the forecast period from 2019 to 2027. Polymyositis is a rare connective tissue disease that causes muscle inflammation, leading to muscle weakness. According to prevalence studies, globally, the incidence of polymyositis is around 1 to 5 per 100,000 individuals, and the prevalence is approximately 5 to 22 per 100,000 individuals. Thus, high awareness related to polymyositis diagnosis and treatment, a strong drug pipeline, and a rising geriatric population is expected to assist the growth of the polymyositis treatment market in the near future.

Abatacept and octagram are expected to grow significantly throughout the forecast period because they are highly efficient compared to currently available drugs.

The pipeline for polymyositis treatment is strong and comprises potential molecules that will drive the growth of the overall market in the near future. Abatacept and octagram (10%) are two of the most potent drugs under phase III clinical trials and are anticipated to perform better than the drugs currently on the market. Abatacept is a human fusion protein of CTLA-4 and the Fc portion of human IgG1 that inhibits the co-stimulation of T cells. Octagam is an immune globulin intravenous (human), and currently, octagon 5% liquid is approved for the treatment of primary humoral immunodeficiency (PI) and other severe combined immunodeficiencies. However, its application for polymyositis treatment is under trial, but results in Phase II trials have been satisfactory in terms of immune system recovery.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Asia Pacific is the fastest growing market due to the rising geriatric population in Japan and increasing awareness related to polymyositis treatment and diagnosis.

During the forecast period from 2019 to 2027, Asia Pacific was identified as the fastest-growing polymyositis treatment market, mainly due to increasing awareness among medical practitioners related to polymyositis and an increasing geriatric population in Japan, China, and South Korea. According to studies, in 2010, the prevalence of polymyositis was estimated to be 13.2 cases per 100,000 individuals in Japan. Japan was identified as the largest polymyositis treatment market due to the rising geriatric population, increasing demand for target-specific drugs, and high awareness related to polymyositis treatment and diagnosis.

Historical and Forecast Period

The polymyositis treatment market was analyzed considering current market trends for the base year of2018, and based on future trends, CAGRs were calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

This report covers the in-depth analysis of the polymyositis treatment market, covering market trends, strategies, and product lifecycles analyzed based on detailed qualitative and quantitative data collected through primary and secondary research. Through primary interviews, industry stakeholders have studied and understood market dynamics such as opportunities, drivers, and challenges further segmented by region and respective countries. This report also includes a comprehensive study of multiple segments of global polymyositis treatment, such as the type of drug class and geography.

Pipeline analysis includes information related to molecules that are under clinical trial and expecting approval in the near future. The report also covers an understanding of the competitive landscape of the major companies present in the polymyositis treatment market, which covers data points such as current and future business strategies, financial data, and the product portfolios of respective companies.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

The major companies present in the market were studied based on recent market updates, product portfolios, financial data, and major strategies. This report also covers attractive investment propositions analyzed with the help of PESTEL analysis, which focuses on in-depth geographical research. Key players operating in the overall report are Hospira, Inc., Antares Pharma, Inc., Medexus Pharma, Inc., Fresenius SE & Co. KGaA, Mylan N.V., Alcami Corporation, Teva Pharmaceuticals, Novartis AG, Genentech, Inc., among others.

Key questions are answered in this report.

Which drug class is in high demand to treat polymyositis, and why?
What are the present market strategies & policies studied & applied by key market players & the competitive landscape of the global polymyositis treatment market?
Which are the crucial and imminent geographical markets (regions and countries) in the polymyositis treatment market, and why?
Which is the largest and fastest-growing region and country globally?
What will be the expected sales of drugs under development?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global PT Market Portraiture
2.2. Global PT Market, by Type of Drug Class, 2018 (US$ Mn)
2.3. Global PT Market, by Geography, 2018 Vs 2027 (Value %)

Chapter 3. Global Polymyositis Treatment (PT) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2018

Chapter 4. Global Polymyositis Treatment (PT) Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
4.1. Overview
4.2. Immunosuppressant
4.2.1. Methotrexate
4.2.2. Azathioprine
4.2.3. Cyclosporine
4.2.4. Tacrolimus
4.2.5. Mycophenolate
4.3. Alkylating Agent
4.3.1. Cyclophosphamide
4.3.2. Chlorambucil
4.4. Immunoglobulin
4.5. Monoclonal Antibodies
4.5.1. Rituximab
4.6. Corticosteroids
4.6.1. Prednisone

Chapter 5. Global Polymyositis Treatment (PT) Market: Pipeline Analysis
5.1. Overview
5.2. Phase III [Till 2027] (U$ Mn)
5.2.1. Ustekinumab
5.2.2. Abatacept
5.2.3. Lenabasum
5.2.4. Octagam 10%
5.2.5. Pirfenidone
5.3. Phase I & II (Qualitative Information)
5.3.1. Tocilizumab (Phase II)
5.3.2. PF-06823859 (Phase II)
5.3.3. IFN-Kinoid (Phase II)
5.3.4. JBT-101 (Phase II)
5.3.5. Tofacitinib (Phase I)
5.3.6. VIB7734 (Phase I)

Chapter 6. Global Polymyositis Treatment (PT) Market, by Geography, 2017 – 2027 (US$ Mn)
6.1. Overview
6.2. North America PT Market Analysis, 2017 – 2027
6.2.1. North America PT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.2.2. North America PT Market, by Country, 2017 – 2027 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe PT Market Analysis, 2017 – 2027
6.3.1. Europe PT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.3.2. Europe PT Market, by Country, 2017 – 2027 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific PT Market Analysis, 2017 – 2027
6.4.1. Asia Pacific PT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.4.2. Asia Pacific PT Market, by Country, 2017 – 2027 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Rest of APAC
6.5. Latin America PT Market Analysis, 2017 – 2027
6.5.1. Latin America PT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.5.2. Latin America PT Market, by Country, 2017 – 2027 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) PT Market Analysis, 2017 – 2027
6.6.1. Middle East & Africa PT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.6.2. MEA PT Market, by Region, 2017 – 2027 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Hospira, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Antares Pharma, Inc.
7.3. Medexus Pharma, Inc.
7.4. Fresenius SE & Co. KGaA
7.5. Mylan N.V.
7.6. Alcami Corporation
7.7. Teva Pharmaceutical Industries Ltd.
7.8. Novartis AG
7.9. Genentech, Inc.
7.10. Bristol-Myers Squibb
7.11. Janssen Pharmaceutical
7.12. Corbus Pharmaceuticals Inc.
7.13. Octapharma
7.14. Beijing Continent Pharmaceutical Co, Ltd.
7.15. Pfizer, Inc.
7.16. Neovacs
7.17. Viela Bio

List of Figures

FIG. 1 Polymyositis Treatment (PT): Market Segmentation
FIG. 2 Global PT Market, by Type of Drug Class, 2018 (US$ Mn)
FIG. 3 Global PT Market, by Geography, 2017 Vs 2027 (US$ Mn)
FIG. 4 Attractive Investment Proposition, by Geography, 2017
FIG. 5 Market Competition Landscape, by Key Players, 2017
FIG. 6 Global Methotrexate Market for PT, 2017 – 2027 (US$ Mn)
FIG. 7 Global Azathioprine Market for PT, 2017 – 2027 (US$ Mn)
FIG. 8 Global Cyclosporine Market for PT, 2017 – 2027 (US$ Mn)
FIG. 9 Global Tacrolimus Market for PT Market, 2017 – 2027 (US$ Mn)
FIG. 10 Global Mycophenolate Market for PT Market, 2017 – 2027 (US$ Mn)
FIG. 11 Global Cyclophosphamide Market for PT, 2017 – 2027 (US$ Mn)
FIG. 12 Global Chlorambucil Market for PT, 2017 – 2027 (US$ Mn)
FIG. 13 Global Immunoglobulin Market for PT, 2017 – 2027 (US$ Mn)
FIG. 14 Global Rituximab Market for PT, 2017 – 2027 (US$ Mn)
FIG. 15 Global Prednisone Market for PT, 2017 – 2027 (US$ Mn)
FIG. 16 Global Ustekinumab Market for PT, Till 2027 (US$ Mn)
FIG. 17 Global Abatacept Market for PT, Till 2027 (US$ Mn)
FIG. 18 Global Lenabasum Market for PT, Till 2027 (US$ Mn)
FIG. 19 Global Octagam 10% Market for PT, Till 2027 (US$ Mn)
FIG. 20 Global Pirfenidone Market for PT, Till 2027 (US$ Mn)
FIG. 21 U.S. PT Market, 2017 – 2027 (US$ Mn)
FIG. 22 Canada PT Market, 2017 – 2027 (US$ Mn)
FIG. 23 U.K. PT Market, 2017 – 2027 (US$ Mn)
FIG. 24 Germany PT Market, 2017 – 2027 (US$ Mn)
FIG. 25 Rest Of Europe PT Market, 2017 – 2027 (US$ Mn)
FIG. 26 Japan PT Market, 2017 – 2027 (US$ Mn)
FIG. 27 China PT Market, 2017 – 2027 (US$ Mn)
FIG. 28 Rest Of Asia Pacific PT Market, 2017 – 2027 (US$ Mn)
FIG. 29 Brazil PT Market, 2017 – 2027 (US$ Mn)
FIG. 30 Mexico PT Market, 2017 – 2027 (US$ Mn)
FIG. 31 Rest Of Latin America PT Market, 2017 – 2027 (US$ Mn)
FIG. 32 GCC PT Market, 2017 – 2027 (US$ Mn)
FIG. 33 Rest Of Middle East And Africa PT Market, 2017 – 2027 (US$ Mn)

List of Tables

TABLE 1 Global Polymyositis Treatment (PT) Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 2 Global Immunosuppressant Market for PT, by Type of Immunosuppressant, 2017 – 2027 (US$ Mn)
TABLE 3 Global Alkylating Agent Market for PT, by Type of Alkylating Agents, 2017 – 2027 (US$ Mn)
TABLE 4 North America PT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 5 North America PT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 6 Europe PT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 7 Europe PT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 8 Asia Pacific PT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 9 Asia Pacific PT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 Latin America PT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 11 Latin America PT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 12 Middle East & Africa PT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 13 Middle East And Africa PT Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 14 Hospira, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Antares Pharma, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Medexus Pharma, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Fresenius SE & Co. KGaA: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Mylan N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Alcami Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Genentech, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Bristol-Myers Squibb: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Janssen Pharmaceutical: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Corbus Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 Octapharma: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 27 Beijing Continent Pharmaceutical Co, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 28 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 29 Neovacs: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 30 Viela Bio: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

Frequently Asked Question

What is the size of Polymyositis Treatment Market?

The market for Polymyositis Treatment Market is expected to reach USD$ XX in 2027.

What is the Polymyositis Treatment Market CAGR?

The Polymyositis Treatment Market is expected to see significant CAGR growth over the coming years, at 5.9%.

What is the Forecast period considered for Polymyositis Treatment Market?

The report is forecasted from 2019 -2027.

What is the base year considered for Polymyositis Treatment Market?

The base year of this report is 2018.

Who are the major players in this market?

Hospira, Inc., Antares Pharma, Inc., Medexus Pharma, Inc., Fresenius SE & Co. KGaA, Mylan N.V., Alcami Corporation, Teva Pharmaceuticals, Novartis AG,are some of the major players in the global market.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$7699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –